Search

Your search keyword '"Santaolalla, Aida"' showing total 190 results
Start Over Author "Santaolalla, Aida"
190 results on '"Santaolalla, Aida"'

1. Utilising high-dimensional data in randomised clinical trials: a review of methods and practice

Author

Cherlin, Svetlana, Bigirumurame, Theophile, Grayling, Michael J, Nsengimana, Jérémie, Ouma, Luke, Santaolalla, Aida, Wan, Fang, Williamson, S Faye, and Wason, James M S

Subjects
Statistics - Applications
Abstract

Introduction: Even in effectively conducted randomised trials, the probability of a successful study remains relatively low. With recent advances in the next-generation sequencing technologies, there is a rapidly growing number of high-dimensional data, including genetic, molecular and phenotypic information, that have improved our understanding of driver genes, drug targets, and drug mechanisms of action. The leveraging of high-dimensional data holds promise for increased success of clinical trials. Methods: We provide an overview of methods for utilising high-dimensional data in clinical trials. We also investigate the use of these methods in practice through a review of recently published randomised clinical trials that utilise high-dimensional genetic data. The review includes articles that were published between 2019 and 2021, identified through the PubMed database. Results: Out of 174 screened articles, 100 (57.5%) were randomised clinical trials that collected high-dimensional data. The most common clinical area was oncology (30%), followed by chronic diseases (28%), nutrition and ageing (18%) and cardiovascular diseases (7%). The most common types of data analysed were gene expression data (70%), followed by DNA data (21%). The most common method of analysis (36.3%) was univariable analysis. Articles that described multivariable analyses used standard statistical methods. Most of the clinical trials had two arms. Discussion: New methodological approaches are required for more efficient analysis of the increasing amount of high-dimensional data collected in randomised clinical trials. We highlight the limitations and barriers to the current use of high-dimensional data in trials, and suggest potential avenues for improvement and future work., Comment: 17 pages, 3 figures, 2 tables

Published
2023

2. Risk of progression following a negative biopsy in prostate cancer active surveillance

Author

Beckmann, Kerri, Santaolalla, Aida, Sugimoto, Mikio, Carroll, Peter, Rubio, Jose, Villers, Arnauld, Bjartell, Anders, Morgan, Todd, Dasgupta, Prokar, Van Hemelrijck, Mieke, and Elhage, Oussama

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Aging, Clinical Research, Cancer, Prostate Cancer, Urologic Diseases, Prevention, Male, Humans, Prostatic Neoplasms, Watchful Waiting, Neoplasm Grading, Biopsy, Logistic Models, Prostate-Specific Antigen, Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium, Urology & Nephrology, Clinical sciences, Oncology and carcinogenesis
Abstract

BackgroundCurrently, follow-up protocols are applied equally to men on active surveillance (AS) for prostate cancer (PCa) regardless of findings at their initial follow-up biopsy. To determine whether less intensive follow-up is suitable following negative biopsy findings, we assessed the risk of converting to active treatment, any subsequent upgrading, volume progression (>33% positive cores), and serious upgrading (grade group >2) for negative compared with positive findings on initial follow-up biopsy.Methods13,161 men from 24 centres participating in the Global Action Plan Active Surveillance Prostate Cancer [GAP3] consortium database, with baseline grade group ≤2, PSA ≤ 20 ng/mL, cT-stage 1-2, diagnosed after 1995, and ≥1 follow-up biopsy, were included in this study. Risk of converting to treatment was assessed using multivariable mixed-effects survival regression. Odds of volume progression, any upgrading and serious upgrading were assessed using mix-effects binary logistic regression for men with ≥2 surveillance biopsies.Results27% of the cohort (n = 3590) had no evidence of PCa at their initial biopsy. Over 50% of subsequent biopsies in this group were also negative. A negative initial biopsy was associated with lower risk of conversion (adjusted hazard ratio: 0.45; 95% confidence interval [CI]: 0.42-0.49), subsequent upgrading (adjusted odds ratio [OR]: 0.52; 95%CI: 0.45-0.62) and serious upgrading (OR: 0.74; 95%CI: 0.59-92). Radiological progression was not assessed due to limited imaging data.ConclusionDespite heterogeneity in follow-up schedules, findings from this global study indicated reduced risk of converting to treatment, volume progression, any upgrading and serious upgrading among men whose initial biopsy findings were negative compared with positive. Given the low risk of progression and high likelihood of further negative biopsy findings, consideration should be given to decreasing follow-up intensity for this group to reduce unnecessary invasive biopsies.

Published
2023

3. Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database

Author

Beckmann, Kerri R, Bangma, Chris H, Helleman, Jozien, Bjartell, Anders, Carroll, Peter R, Morgan, Todd, Nieboer, Daan, Santaolalla, Aida, Trock, Bruce J, Valdagni, Riccardo, Roobol, Monique J, Trock, Bruce, Ehdaie, Behfar, Carroll, Peter, Filson, Christopher, Logothetis, Christopher, Klotz, Laurence, Pickles, Tom, Hyndman, Eric, Moore, Caroline, Gnanapragasam, Vincent, Van Hemelrijck, Mieke, Dasgupta, Prokar, Bangma, Chris, Roobol, Monique, Villers, Arnauld, Robert, Grégoire, Semjonow, Axel, Rannikko, Antti, Perry, Antoinette, Hugosson, Jonas, Rubio‐Briones, Jose, Hefermehl, Lukas, Shiong, Lee Lui, Frydenberg, Mark, Stricker, Phillip, Sugimoto, Mikio, Chung, Byung Ha, van der Kwast, Theo, van der Linden, Wim, Hulsen, Tim, Ruwe, Boris, van Hooft, Peter, Steyerberg, Ewout, Beckmann, Kerri, Denton, Brian, Hayen, Andrew, Boutros, Paul, Guo, Wei, Benfante, Nicole, Cowan, Janet, Patil, Dattatraya, Park, Lauren, Ferrante, Stephanie, Mamedov, Alexandre, LaPointe, Vincent, Crump, Trafford, Stavrinides, Vasilis, Kimberly‐Duffell, Jenna, Olivier, Jonathan, Rancati, Tiziana, Ahlgren, Helén, Mascarós, Juanma, Löfgren, Annica, Lehmann, Kurt, Lin, Catherine Han, Cusick, Thomas, Hirama, Hiromi, Lee, Kwang Suk, Jenster, Guido, Auvinen, Anssi, Haider, Masoom, van Bochove, Kees, Kouspou, Michelle, and Paich, Kellie

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Urologic Diseases, Aging, Prevention, Cancer, Prostate Cancer, Clinical Research, Biopsy, Disease Progression, Humans, Male, Neoplasm Grading, Prostate, Prostate-Specific Antigen, Prostatic Neoplasms, Watchful Waiting, active surveillance, biopsy schedule, prostate cancer, treatment, upgrading, Global Action Plan Active Surveillance Prostate Cancer [G.A.P.3] Consortium, Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

BackgroundThe optimal interval for repeat biopsy during active surveillance (AS) for prostate cancer is yet to be defined. This study examined whether risk of upgrading (to grade group ≥ 2) or risk of converting to treatment varied according to intensity of repeat biopsy using data from the GAP3 consortium's global AS database.Materials and methodsIntensity of surveillance biopsy schedules was categorized according to centers' protocols: (a) Prostate Cancer Research International Active Surveillance project (PRIAS) protocols with biopsies at years 1, 4, and 7 (10 centers; 7532 men); (b) biennial biopsies, that is, every other year (8 centers; 4365 men); and (c) annual biopsy schedules (4 centers; 1602 men). Multivariable Cox regression was used to compare outcomes according to biopsy intensity.ResultsOut of the 13,508 eligible participants, 56% were managed according to PRIAS protocols (biopsies at years 1, 4, and 7), 32% via biennial biopsy, and 12% via annual biopsy. After adjusting for baseline characteristics, risk of converting to treatment was greater for those on annual compared with PRIAS biopsy schedules (hazard ratio [HR] = 1.66; 95% confidence interval [CI] = 1.51-1.83; p

Published
2022

4. Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium

Author

Olivier, Jonathan, Li, Weiyu, Nieboer, Daan, Helleman, Jozien, Roobol, Monique, Gnanapragasam, Vincent, Frydenberg, Mark, Sugimoto, Mikio, Carroll, Peter, Morgan, Todd M, Valdagni, Riccardo, Rubio-Briones, Jose, Robert, Grégoire, Stricker, Phillip, Hayen, Andrew, Schoots, Ivo, Haider, Masoom, Moore, Caroline M, Denton, Brian, Villers, Arnauld, Trock, Bruce, Ehdaie, Behfar, Filson, Christopher, Logothetis, Christopher, Morgan, Todd, Klotz, Laurence, Pickles, Tom, Hyndman, Eric, Van Hemelrijck, Mieke, Dasgupta, Prokar, Bangma, Chris, Semjonow, Axel, Rannikko, Antti, Perry, Antoinette, Hugosson, Jonas, Bjartell, Anders, Hefermehl, Lukas, Shiong, Lee Lui, Chung, Byung Ha, van der Kwast, Theo, Hulsen, Tim, van der Linden, Wim, Ruwe, Boris, van Hooft, Peter, Steyerberg, Ewout, Boutros, Paul, Guo, Wei, Benfante, Nicole, Cowan, Janet, Patil, Dattatraya, Park, Lauren, Ferrante, Stephanie, Mamedov, Alexandre, LaPointe, Vincent, Crump, Trafford, Stavrinides, Vasilis, Kimberly-Duffell, Jenna, Santaolalla, Aida, Rancati, Tiziana, Ahlgren, Helén, Mascarós, Juanma, Löfgren, Annica, Lehmann, Kurt, Lin, Catherine Han, Cusick, Thomas, Hirama, Hiromi, Lee, Kwang Suk, Jenster, Guido, Auvinen, Anssi, van Bochove, Kees, Kouspou, Michelle, and Paich, Kellie

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Prevention, Clinical Research, Biomedical Imaging, Clinical Trials and Supportive Activities, Aging, Cancer, Urologic Diseases, Prostate Cancer, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, Magnetic resonance imaging, Prostate cancer, Active surveillance, Discontinuation, Worldwide, Nomogram, Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 Consortium, Urology & Nephrology, Clinical sciences
Abstract

BackgroundThe inclusion criterion for active surveillance (AS) is low- or intermediate-risk prostate cancer. The predictive value of the presence of a suspicious lesion at magnetic resonance imaging (MRI) at the time of inclusion is insufficiently known.ObjectiveTo evaluate the percentage of patients needing active treatment stratified by the presence or absence of a suspicious lesion at baseline MRI.Design setting and participantsA retrospective analysis of the data from the multicentric AS GAP3 Consortium database was conducted. The inclusion criteria were men with grade group (GG) 1 or GG 2 prostate cancer combined with prostate-specific antigen

Published
2022

6. Comparison of Characteristics, Follow-up and Outcomes of Active Surveillance for Prostate Cancer According to Ethnicity in the GAP3 Global Consortium Database.

Author

Beckmann, Kerri, Santaolalla, Aida, Helleman, Jozien, Carroll, Peter, Ha Chung, Byung, Shiong Lee, Lui, Perry, Antoinette, Rubio-Briones, Jose, Sugimoto, Mikio, Trock, Bruce, Valdagni, Riccardo, Dasgupta, Prokar, Van Hemelrijck, Mieke, Elhage, Oussama, and Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium

Subjects
Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium, Active surveillance, Ethnicity, Outcomes, Prostate cancer, Race, Clinical Research, Urologic Diseases, Prostate Cancer, Cancer, Aging, Prevention
Abstract

BackgroundStudies of active surveillance (AS) for prostate cancer (PCa) have focussed predominantly on Caucasian populations. Little is known about the experience of Asian men, while suitability for men of African descent has been questioned.ObjectiveTo compare baseline characteristics, follow-up, and outcomes for men on AS for PCa, according to ethnicity.Design setting and participantsThe study cohort included 13 centres from the GAP3 consortium that record ethnicity (categorised broadly as Caucasian/white, African/Afro-Caribbean/black, Asian, mixed/other, and unknown). Men with biopsy grade group >2, prostate-specific antigen (PSA) >20 ng/ml, T stage ≥cT3, or age >80 yr were excluded.Outcome measurements and statistical analysisClinical characteristics, follow-up schedules, outcome status, and reasons for discontinuation were compared across ethnic groups. Risk of upgrading, potential disease progression (grade group ≥3 or T stage ≥3), suspicious indications (any upgrading, number of positive cores >3, T stage ≥cT3, PSA >20 ng/ml, or PSA density >0.2 ng/ml/cc2), and conversion to treatment were assessed using mixed-effect regression models.Results and limitationsThe eligible cohort (n = 9158) comprised 83% Caucasian men, 6% men of African descent, 5% Asian men, 2% men of mixed/other ethnicity, and 4% men of unknown ethnicity. Risks of suspicious indicators (hazard ratio = 1.27; 95% confidence interval [CI] 1.12-1.45), upgrading (odds ratio [OR] = 1.40; 95% CI 1.14-1.71), and potential progression (OR = 1.46; 95% CI 1.06-2.01) were higher among African/black than among Caucasian/white men. Risk of transitioning to treatment did not differ by ethnicity. More Asian than Caucasian men converted without progression (42% vs 26%, p < 0.001). Heterogeneity in surveillance protocols and racial makeup limit interpretation.ConclusionsThis multinational study found differences in the risk of disease progression and transitioning to treatment without signs of progression between ethnic groups. Further research is required to determine whether differences are due to biology, sociocultural factors, and/or clinical practice.Patient summaryThis international study compared prostate cancer active surveillance outcomes by ethnicity. Risks of upgrading and disease progression were higher among African than among Caucasian men. Transitioning to treatment without progression was highest among Asian men. Understanding of these differences requires further investigation.

Published
2021

7. Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes

Author

Bax, Heather J., Chauhan, Jitesh, Stavraka, Chara, Santaolalla, Aida, Osborn, Gabriel, Khiabany, Atousa, Grandits, Melanie, López-Abente, Jacobo, Palhares, Lais C. G. F., Chan Wah Hak, Charleen, Robinson, Alexandra, Pope, Amy, Woodman, Natalie, Naceur-Lombardelli, Cristina, Malas, Sadek, Coumbe, Jack E. M., Nakamura, Mano, Laddach, Roman, Mele, Silvia, Crescioli, Silvia, Black, Anna M., Lombardi, Sara, Canevari, Silvana, Figini, Mariangela, Sayasneh, Ahmad, Tsoka, Sophia, FitzGerald, Kevin, Gillett, Cheryl, Pinder, Sarah, Van Hemelrijck, Mieke, Kristeleit, Rebecca, Ghosh, Sharmistha, Montes, Ana, Spicer, James, Karagiannis, Sophia N., and Josephs, Debra H.

Published
2023
Full Text
View/download PDF

8. Update on the prognostic value of a novel immune-related toxicity grading system (OST score) in patients with advanced solid tumours treated with immune checkpoint inhibitors (ICI).

Author

Kapiris, Matthaios, primary, Santaolalla, Aida, additional, Bratsos, Sosipatros, additional, Guhnam, Sundeep, additional, McDonald, Louisa, additional, Fitzpatrick-Greening, Mary, additional, Muhith, Moe, additional, Wu, Yin, additional, Georgiou, Alexandros, additional, Josephs, Debra Hannah, additional, Sarker, Debashis, additional, and Cope, Andrew, additional

Published
2024
Full Text
View/download PDF

9. Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium

Author

Van Hemelrijck, Mieke, Ji, Xi, Helleman, Jozien, Roobol, Monique J, van der Linden, Wim, Nieboer, Daan, Bangma, Chris H, Frydenberg, Mark, Rannikko, Antti, Lee, Lui S, Gnanapragasam, Vincent J, Kattan, Mike W, Trock, Bruce, Ehdaie, Behfar, Carroll, Peter, Filson, Christopher, Kim, Jeri, Logothetis, Christopher, Morgan, Todd, Klotz, Laurence, Pickles, Tom, Hyndman, Eric, Moore, Caroline M, Gnanapragasam, Vincent, Dasgupta, Prokar, Bangma, Chris, Roobol, Monique, Villers, Arnauld, Valdagni, Riccardo, Perry, Antoinette, Hugosson, Jonas, Rubio-Briones, Jose, Bjartell, Anders, Hefermehl, Lukas, Shiong, Lee Lui, Kakehi, Yoshiyuki, Chung, Byung Ha, van der Kwast, Theo, Obbink, Henk, Hulsen, Tim, de Jonge, Cees, Kattan, Mike, Xinge, Ji, Muir, Kenneth, Lophatananon, Artitaya, Fahey, Michael, Steyerberg, Ewout, Zhang, Liying, Santa Olalla, Aida, Beckmann, Kerri, Denton, Brian, Hayen, Andrew, Boutros, Paul, Guo, Wei, Benfante, Nicole, Cowan, Janet, Patil, Dattatraya, Tolosa, Emily, Kim, Tae-Kyung, Mamedov, Alexandre, La Pointe, Vincent, Crump, Trafford, Kimberly-Duffell, Jenna, Santaolalla, Aida, Olivier, Jonathan, Rancati, Tiziana, Ahlgren, Helén, Mascarós, Juanma, Löfgren, Annica, Lehmann, Kurt, Lin, Catherine Han, Hirama, Hiromi, Lee, Kwang Suk, Jenster, Guido, Auvinen, Anssi, Haider, Masoom, van Bochove, Kees, Carter, Ballentine, Gledhill, Sam, Buzza, Mark, and Bruinsma, Sophie

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Prostate Cancer, Aging, Prevention, Urologic Diseases, Cancer, Good Health and Well Being, Aged, Asia, Australia, Biopsy, Cause of Death, Clinical Decision-Making, Databases, Factual, Disease Progression, Early Detection of Cancer, Europe, Humans, Kallikreins, Male, Middle Aged, North America, Patient Dropouts, Predictive Value of Tests, Prostate-Specific Antigen, Prostatic Neoplasms, Risk Assessment, Risk Factors, Time Factors, Watchful Waiting, Prostate cancer, Active surveillance, Discontinuation, Worldwide, Members of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 consortium, Urology & Nephrology, Clinical sciences
Abstract

BackgroundCareful assessment of the reasons for discontinuation of active surveillance (AS) is required for men with prostate cancer (PCa).ObjectiveUsing Movember's Global Action Plan Prostate Cancer Active Surveillance initiative (GAP3) database, we report on reasons for AS discontinuation.Design, setting, and participantsWe compared data from 10296 men on AS from 21 centres across 12 countries.Outcome measurements and statistical analysisCumulative incidence methods were used to estimate the cumulative incidence rates of AS discontinuation.Results and limitationsDuring 5-yr follow-up, 27.5% (95% confidence interval [CI]: 26.4-28.6%) men showed signs of disease progression, 12.8% (95% CI: 12.0-13.6%) converted to active treatment without evidence of progression, 1.7% (95% CI: 1.5-2.0%) continued to watchful waiting, and 1.7% (95% CI: 1.4-2.1%) died from other causes. Of the 7049 men who remained on AS, 2339 had follow-up for >5yr, 4561 had follow-up for

Published
2019

10. Active Surveillance for Men Younger than 60 Years or with Intermediate-risk Localized Prostate Cancer. Descriptive Analyses of Clinical Practice in the Movember GAP3 Initiative

Author

Trock, Bruce, Ehdaie, Behfar, Carroll, Peter, Filson, Christopher, Logothetis, Christopher, Morgan, Todd, Klotz, Laurence, Pickles, Tom, Hyndman, Eric, Moore, Caroline, Gnanapragasam, Vincent, Van Hemelrijck, Mieke, Dasgupta, Prokar, Bangma, Chris, Roobol, Monique, Villers, Arnauld, Robert, Grégoire, Semjonow, Axel, Rannikko, Antti, Valdagni, Riccardo, Perry, Antoinette, Hugosson, Jonas, Rubio-Briones, Jose, Bjartell, Anders, Hefermehl, Lukas, Lui Shiong, Lee, Frydenberg, Mark, Stricker, Phillip, Sugimoto, Mikio, Ha Chung, Byung, van der Kwast, Theo, van der Linden, Wim, Hulsen, Tim, Ruwe, Boris, Peter van Hooft, Steyerberg, Ewout, Nieboer, Daan, Beckmann, Kerri, Denton, Brian, Hayen, Andrew, Boutros, Paul, Guo, Wei, Benfante, Nicole, Cowan, Janet, Patil, Dattatraya, Park, Lauren, Ferrante, Stephanie, Mamedov, Alexandre, LaPointe, Vincent, Crump, Trafford, Stavrinides, Vasilis, Kimberly-Duffell, Jenna, Santaolalla, Aida, Olivier, Jonathan, Rancati, Tiziana, Ahlgren, Helén, Mascarós, Juanma, Löfgren, Annica, Lehmann, Kurt, Han Lin, Catherine, Cusick, Thomas, Hirama, Hiromi, Suk Lee, Kwang, Jenster, Guido, Auvinen, Anssi, Haider, Masoom, van Bochove, Kees, Kouspou, Michelle, Paich, Kellie, Helleman, Jozien, Remmers, Sebastiaan, Hyndman, Matthew E., Moore, Caroline M., Shiong Lee, Lui, Elhage, Oussama, Morgan, Todd M., Bangma, Chris H., and Roobol, Monique J.

Published
2022
Full Text
View/download PDF

12. Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium

Author

Trock, Bruce, Ehdaie, Behfar, Carroll, Peter, Filson, Christopher, Logothetis, Christopher, Morgan, Todd, Klotz, Laurence, Pickles, Tom, Hyndman, Eric, Moore, Caroline M, Gnanapragasam, Vincent, Van Hemelrijck, Mieke, Dasgupta, Prokar, Bangma, Chris, Roobol, Monique, Villers, Arnauld, Robert, Grégoire, Semjonow, Axel, Rannikko, Antti, Valdagni, Riccardo, Perry, Antoinette, Hugosson, Jonas, Rubio-Briones, Jose, Bjartell, Anders, Hefermehl, Lukas, Lui Shiong, Lee, Frydenberg, Mark, Stricker, Phillip, Sugimoto, Mikio, Ha Chung, Byung, van der Kwast, Theo, Hulsen, Tim, van der Linden, Wim, Ruwe, Boris, van Hooft, Peter, Steyerberg, Ewout, Nieboer, Daan, Denton, Brian, Hayen, Andrew, Boutros, Paul, Guo, Wei, Benfante, Nicole, Cowan, Janet, Patil, Dattatraya, Park, Lauren, Ferrante, Stephanie, Mamedov, Alexandre, LaPointe, Vincent, Crump, Trafford, Stavrinides, Vasilis, Kimberly-Duffell, Jenna, Santaolalla, Aida, Olivier, Jonathan, Rancati, Tiziana, Ahlgren, Helén, Mascarós, Juanma, Löfgren, Annica, Lehmann, Kurt, Han Lin, Catherine, Cusick, Thomas, Hirama, Hiromi, Suk Lee, Kwang, Jenster, Guido, Auvinen, Anssi, Haider, Masoom, van Bochove, Kees, Kouspou, Michelle, Paich, Kellie, Helleman, Jozien, Li, Weiyu, Morgan, Todd M., Schoots, Ivo, and Moore, Caroline M.

Published
2022
Full Text
View/download PDF

14. Comparison of Characteristics, Follow-up and Outcomes of Active Surveillance for Prostate Cancer According to Ethnicity in the GAP3 Global Consortium Database

Author

Trock, Bruce, Ehdaie, Behfar, Carroll, Peter, Filson, Christopher, Logothetis, Christopher, Morgan, Todd, Klotz, Laurence, Pickles, Tom, Hyndman, Eric, Moore, Caroline, Gnanapragasam, Vincent, Van Hemelrijck, Mieke, Dasgupta, Prokar, Bangma, Chris, Roobol, Monique, Villers, Arnauld, Robert, Grégoire, Semjonow, Axel, Rannikko, Antti, Valdagni, Riccardo, Perry, Antoinette, Hugosson, Jonas, Rubio-Briones, Jose, Bjartell, Anders, Hefermehl, Lukas, Lui Shiong, Lee, Frydenberg, Mark, Stricker, Phillip, Sugimoto, Mikio, Ha Chung, Byung, van der Kwast, Theo, van der Linden, Wim, Hulsen, Tim, Ruwe, Boris, van Hooft, Peter, Steyerberg, Ewout, Nieboer, Daan, Beckmann, Kerri, Denton, Brian, Hayen, Andrew, Boutros, Paul, Guo, Wei, Benfante, Nicole, Cowan, Janet, Patil, Dattatraya, Park, Lauren, Ferrante, Stephanie, Mamedov, Alexandre, LaPointe, Vincent, Crump, Trafford, Stavrinides, Vasilis, Kimberly-Duffell, Jenna, Santaolalla, Aida, Olivier, Jonathan, Rancati, Tiziana, Ahlgren, Helén, Mascarós, Juanma, Löfgren, Annica, Lehmann, Kurt, Han Lin, Catherine, Cusick, Thomas, Hirama, Hiromi, Suk Lee, Kwang, Jenster, Guido, Auvinen, Anssi, Haider, Masoom, van Bochove, Kees, Kouspou, Michelle, Paich, Kellie, Helleman, Jozien, Shiong Lee, Lui, and Elhage, Oussama

Published
2021
Full Text
View/download PDF

17. Anxiety and depression in patients with non-site-specific cancer symptoms: data from a rapid diagnostic clinic.

Author

Monroy-Iglesias, Maria J., Russell, Beth, Martin, Sabine, Fox, Louis, Moss, Charlotte, Bruno, Flaminia, Millwaters, Juliet, Steward, Lindsay, Murtagh, Colette, Cargaleiro, Carlos, Bater, Darren, Lavelle, Grace, Simpson, Anna, Onih, Jemima, Haire, Anna, Reeder, Clare, Jones, Geraint, Smith, Sue, Santaolalla, Aida, and Van Hemelrijck, Mieke

Subjects
MENTAL depression, ANXIETY, MACHINE learning, CANCER patients, ANXIETY disorders, SUPPORT vector machines
Abstract

Background: Rapid diagnostic clinics (RDCs) provide a streamlined holistic pathway for patients presenting with non-site specific (NSS) symptoms concerning of malignancy. The current study aimed to: 1) assess the prevalence of anxiety and depression, and 2) identify a combination of patient characteristics and symptoms associated with severe anxiety and depression at Guy's and St Thomas' Foundation Trust (GSTT) RDC in Southeast London. Additionally, we compared standard statistical methods with machine learning algorithms for predicting severe anxiety and depression. Methods: Patients seen at GSTT RDC between June 2019 and January 2023 completed the General Anxiety Disorder Questionnaire (GAD-7) and Patient Health Questionnaire (PHQ-8) questionnaires, at baseline. We used logistic regression (LR) and 2 machine learning (ML) algorithms (random forest (RF), support vector machine (SVM)) to predict risk of severe anxiety and severe depression. The models were constructed using a set of sociodemographic and clinical variables. Results: A total of 1734 patients completed GAD-7 and PHQ-8 questionnaires. Of these, the mean age was 59 years (Standard Deviation: 15.5), and 61.5% (n:1067) were female. Prevalence of severe anxiety (GAD-7 score ≥15) was 13.8% and severe depression (PHQ-8 score≥20) was 9.3%. LR showed that a combination of previous mental health condition (PMH, Adjusted Odds Rario (AOR) 3.28; 95% confidence interval (CI) 2.36-4.56), symptom duration >6 months (AOR 2.20; 95%CI 1.28-3.77), weight loss (AOR 1.88; 95% CI 1.362.61), progressive pain (AOR 1.71; 95%CI 1.26-2.32), and fatigue (AOR 1.36; 95%CI 1.01-1.84), was positively associated with severe anxiety. Likewise, a combination PMH condition (AOR 3.95; 95%CI 2.17-5.75), fatigue (AOR 2.11; 95%CI 1.47-3.01), symptom duration >6 months (AOR 1.98; 95%CI 1.06-3.68), weight loss (AOR 1.66; 95%CI 1.13-2.44), and progressive pain (AOR 1.50; 95%CI 1.04-2.16), was positively associated with severe depression. LR and SVM had highest accuracy levels for severe anxiety (LR: 86%, SVM: 85%) and severe depression (SVM: 89%, LR: 86%). Conclusion: High prevalence of severe anxiety and severe depression was found. PMH, fatigue, weight loss, progressive pain, and symptoms >6 months emerged as combined risk factors for both these psychological comorbidities. RDCs offer an opportunity to alleviate distress in patients with concerning symptoms by expediting diagnostic evaluations. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Immune‐monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium.

Author

Tentori, Cristina A., Zhao, Lin P., Tinterri, Benedetta, Strange, Kathryn E., Zoldan, Katharina, Dimopoulos, Konstantinos, Feng, Xingmin, Riva, Elena, Lim, Benjamin, Simoni, Yannick, Murthy, Vidhya, Hayes, Madeline J., Poloni, Antonella, Padron, Eric, Cardoso, Bruno A., Cross, Michael, Winter, Susann, Santaolalla, Aida, Patel, Bhavisha A., and Groarke, Emma M.

Published
2024
Full Text
View/download PDF

19. Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance Initiative

Author

Trock, Bruce, Ehdaie, Behfar, Carroll, Peter, Filson, Christopher, Kim, Jeri, Logothetis, Christopher, Morgan, Todd, Klotz, Laurence, Pickles, Tom, Hyndman, Eric, Moore, Caroline M., Gnanapragasam, Vincent, Van Hemelrijck, Mieke, Dasgupta, Prokar, Bangma, Chris, Roobol, Monique, Villers, Arnauld, Rannikko, Antti, Valdagni, Riccardo, Perry, Antoinette, Hugosson, Jonas, Rubio-Briones, Jose, Bjartell, Anders, Hefermehl, Lukas, Shiong, Lee Lui, Frydenberg, Mark, Kakehi, Yoshiyuki, Chung, Byung Ha, van der Kwast, Theo, Obbink, Henk, van der Linden, Wim, Hulsen, Tim, Jonge, Cees de, Kattan, Mike, Xinge, Ji, Muir, Kenneth, Lophatananon, Artitaya, Fahey, Michael, Steyerberg, Ewout, Nieboer, Daan, Zhang, Liying, Beckmann, Kerri, Denton, Brian, Hayen, Andrew, Boutros, Paul, Guo, Wei, Benfante, Nicole, Cowan, Janet, Patil, Dattatraya, Tolosa, Emily, Kim, Tae-Kyung, Mamedov, Alexandre, LaPointe, Vincent, Crump, Trafford, Kimberly-Duffell, Jenna, Santaolalla, Aida, Olivier, Jonathan, Rancati, Tiziana, Ahlgren, Helén, Mascarós, Juanma, Löfgren, Annica, Lehmann, Kurt, Lin, Catherine Han, Hirama, Hiromi, Lee, Kwang Suk, Jenster, Guido, Auvinen, Anssi, Haider, Masoom, van Bochove, Kees, Carter, Ballentine, Gledhill, Sam, Buzza, Mark, Bruinsma, Sophie, Helleman, Jozien, Kalapara, Arveen A., Verbeek, Jan F.M., Lee, Lui Shiong, Bangma, Chris H., Steyerberg, Ewout W., Harkin, Tim, and Roobol, Monique J.

Published
2020
Full Text
View/download PDF

21. Reply to R. Sun et al

Author

Moore, Jonathan L., primary, Santaolalla, Aida, additional, Van Hemelrijck, Mieke, additional, North, Bernard, additional, and Davies, Andrew R., additional

Published
2023
Full Text
View/download PDF

26. Prevalence of MRI lesions in men responding to a GP-led invitation for a prostate health check: a prospective cohort study

Author

Moore, Caroline M, primary, Frangou, Elena, additional, McCartan, Neil, additional, Santaolalla, Aida, additional, Kopcke, Douglas, additional, Brembilla, Giorgio, additional, Hadley, Joanna, additional, Giganti, Francesco, additional, Marsden, Teresa, additional, Van Hemelrijck, Mieke, additional, Gong, Fiona, additional, Freeman, Alex, additional, Haider, Aiman, additional, Tuck, Steve, additional, Pashayan, Nora, additional, Callender, Thomas, additional, Green, Saran, additional, Brown, Louise C, additional, Punwani, Shonit, additional, and Emberton, Mark, additional

Published
2023
Full Text
View/download PDF

27. Redefining Cancer Research Priorities in Low- and Middle-Income Countries in the Post–COVID-19 Global Context: A Modified Delphi Consensus Process

Author

Fox, Louis, primary, Santaolalla, Aida, additional, Handford, Jasmine, additional, Sullivan, Richard, additional, Torode, Julie, additional, Vanderpuye, Verna, additional, Pramesh, C.S., additional, Mula-Hussain, Layth, additional, AlWaheidi, Shaymaa, additional, Makaroff, Lydia E., additional, Kaur, Ranjit, additional, Mackay, Clara, additional, Mukherji, Deborah, additional, and Van Hemelrijck, Mieke, additional

Published
2023
Full Text
View/download PDF

28. MRI-based nomogram for the prediction of prostate cancer diagnosis: A multi-centre validated patient–physician decision tool.

Author

Chau, Edwin M, Russell, Beth, Santaolalla, Aida, Van Hemelrijck, Mieke, McCracken, Stuart, Page, Toby, Liyanage, Sidath H, Aning, Jonathan, Gnanapragasam, Vincent J, and Acher, Peter

Abstract

Objective: To update and externally validate a magnetic resonance imaging (MRI)-based nomogram for predicting prostate biopsy outcomes with a multi-centre cohort. Materials and methods: Prospective data from five UK-based centres were analysed. All men were biopsy naïve. Those with missing data, no MRI, or prostate-specific antigen (PSA) > 30 ng/mL were excluded. Logistic regression analysis was used to confirm predictors of prostate cancer outcomes including MRI-PIRADS (Prostate Imaging Reporting and Data System) score, PSA density, and age. Clinically significant disease was defined as International Society of Urological Pathology (ISUP) Grade Group ⩾ 2 (Gleason grade ⩾ 7). Biopsy strategy included transrectal and transperineal approaches. Nomograms were produced using logistic regression analysis results. Results: A total of 506 men were included in the analysis with median age 66 (interquartile range (IQR) = 60–69). Median PSA was 6.6 ng/mL (IQR = 4.72–9.26). PIRADS ⩾ 3 was reported in 387 (76.4%). Grade Group ⩾ 2 detection was 227 (44.9%) and 318 (62.8%) for any cancer. Performance of the MRI-based nomogram was an area under curve (AUC) of 0.84 (95% confidence interval (CI) = 0.81–0.88) for Grade Group ⩾ 2% and 0.85 (95% CI = 0.82–0.88) for any prostate cancer. Conclusion: We present external validation of a novel MRI-based nomogram in a multi-centre UK-based cohort, showing good discrimination in identifying men at high risk of having clinically significant disease. These findings support this risk calculator use in the prostate biopsy decision-making process. Level of evidence: 2c [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

29. Pathologic Lymph Node Regression After Neoadjuvant Chemotherapy Predicts Recurrence and Survival in Esophageal Adenocarcinoma: A Multicenter Study in the United Kingdom.

Author

Moore, Jonathan L., Green, Michael, Santaolalla, Aida, Deere, Harriet, Evans, Richard P.T., Elshafie, Mona, Lavery, Anita, McManus, Damian T., McGuigan, Andrew, Douglas, Rosalie, Horne, Joanne, Walker, Robert, Mir, Hira, Terlizzo, Monica, Kamarajah, Sivesh K., Van Hemelrijck, Mieke, Maisey, Nick, Sita-Lumsden, Ailsa, Ngan, Sarah, and Kelly, Mark

Published
2023
Full Text
View/download PDF

30. Supplementary materials and methods and Supplementary figure legends revised from Tumor-Infiltrating B Lymphocyte Profiling Identifies IgG-Biased, Clonally Expanded Prognostic Phenotypes in Triple-Negative Breast Cancer

Author

Harris, Robert J., primary, Cheung, Anthony, primary, Ng, Joseph C.F., primary, Laddach, Roman, primary, Chenoweth, Alicia M., primary, Crescioli, Silvia, primary, Fittall, Matthew, primary, Dominguez-Rodriguez, Diana, primary, Roberts, James, primary, Levi, Dina, primary, Liu, Fangfang, primary, Alberts, Elena, primary, Quist, Jelmar, primary, Santaolalla, Aida, primary, Pinder, Sarah E., primary, Gillett, Cheryl, primary, Hammar, Niklas, primary, Irshad, Sheeba, primary, Van Hemelrijck, Mieke, primary, Dunn-Walters, Deborah K., primary, Fraternali, Franca, primary, Spicer, James F., primary, Lacy, Katie E., primary, Tsoka, Sophia, primary, Grigoriadis, Anita, primary, Tutt, Andrew N.J., primary, and Karagiannis, Sophia N., primary

Published
2023
Full Text
View/download PDF

31. Supplementary tables and figures from Tumor-Infiltrating B Lymphocyte Profiling Identifies IgG-Biased, Clonally Expanded Prognostic Phenotypes in Triple-Negative Breast Cancer

Author

Harris, Robert J., primary, Cheung, Anthony, primary, Ng, Joseph C.F., primary, Laddach, Roman, primary, Chenoweth, Alicia M., primary, Crescioli, Silvia, primary, Fittall, Matthew, primary, Dominguez-Rodriguez, Diana, primary, Roberts, James, primary, Levi, Dina, primary, Liu, Fangfang, primary, Alberts, Elena, primary, Quist, Jelmar, primary, Santaolalla, Aida, primary, Pinder, Sarah E., primary, Gillett, Cheryl, primary, Hammar, Niklas, primary, Irshad, Sheeba, primary, Van Hemelrijck, Mieke, primary, Dunn-Walters, Deborah K., primary, Fraternali, Franca, primary, Spicer, James F., primary, Lacy, Katie E., primary, Tsoka, Sophia, primary, Grigoriadis, Anita, primary, Tutt, Andrew N.J., primary, and Karagiannis, Sophia N., primary

Published
2023
Full Text
View/download PDF

35. OGC P20 Metabolic tumour and nodal response to neoadjuvant chemotherapy on FDG PET-CT as a predictor of pathological response and survival in patients undergoing surgical resection for locally advanced oesophageal adenocarcinoma

Author

Moore, Jonathan, primary, Subesinghe, Manil, additional, Santaolalla, Aida, additional, Green, Michael, additional, Deere, Harriet, additional, Van Hemelrijck, Mieke, additional, Lagergren, Jesper, additional, Chicklore, Sugama, additional, Maisey, Nick, additional, Gossage, James, additional, Kelly, Mark, additional, Baker, Cara, additional, and Davies, Andrew, additional

Published
2022
Full Text
View/download PDF

36. OGC O02 The prognostic effect of pathological lymph node regression after neoadjuvant chemotherapy for oesophageal adenocarcinoma – a multicentre study

Author

Moore, Jonathan, primary, Green, Michael, additional, Deere, Harriet, additional, Santaolalla, Aida, additional, Evans, Richard, additional, Elshafie, Mona, additional, Lavery, Anita, additional, McGuigan, Andrew, additional, McManus, Damian, additional, Horne, Joanne, additional, Walker, Robert, additional, Mir, Hira, additional, Terlizzo, Monica, additional, Kamarajah, Sivesh, additional, Van Hemelrijck, Mieke, additional, Maisey, Nick, additional, Lumsden, Ailsa, additional, Ngan, Sarah, additional, Kelly, Mark, additional, Baker, Cara, additional, Kumar, Sacheen, additional, Lagergren, Jesper, additional, Allum, William, additional, Gossage, James, additional, Griffiths, Ewan, additional, Grabsch, Heike, additional, Turkington, Richard, additional, Underwood, Tim, additional, Smyth, Elizabeth, additional, Fitzgerald, Rebecca, additional, Cunningham, David, additional, and Davies, Andrew, additional

Published
2022
Full Text
View/download PDF

37. Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes

Author

Bax, Heather J., primary, Chauhan, Jitesh, additional, Stavraka, Chara, additional, Santaolalla, Aida, additional, Osborn, Gabriel, additional, Khiabany, Atousa, additional, Grandits, Melanie, additional, López-Abente, Jacobo, additional, Palhares, Lais C. G. F., additional, Chan Wah Hak, Charleen, additional, Robinson, Alexandra, additional, Pope, Amy, additional, Woodman, Natalie, additional, Naceur-Lombardelli, Cristina, additional, Malas, Sadek, additional, Coumbe, Jack E. M., additional, Nakamura, Mano, additional, Laddach, Roman, additional, Mele, Silvia, additional, Crescioli, Silvia, additional, Black, Anna M., additional, Lombardi, Sara, additional, Canevari, Silvana, additional, Figini, Mariangela, additional, Sayasneh, Ahmad, additional, Tsoka, Sophia, additional, FitzGerald, Kevin, additional, Gillett, Cheryl, additional, Pinder, Sarah, additional, Van Hemelrijck, Mieke, additional, Kristeleit, Rebecca, additional, Ghosh, Sharmistha, additional, Montes, Ana, additional, Spicer, James, additional, Karagiannis, Sophia N., additional, and Josephs, Debra H., additional

Published
2022
Full Text
View/download PDF

38. 568. THE PROGNOSTIC EFFECT OF PATHOLOGICAL LYMPH NODE REGRESSION AFTER NEOADJUVANT CHEMOTHERAPY FOR OESOPHAGEAL ADENOCARCINOMA – A MULTICENTRE STUDY

Author

Moore, Jonathan, primary, Green, Michael, additional, Van Hemelrijck, Mieke, additional, Deere, Harriet, additional, Evans, Richard PT, additional, Elshafie, Mona, additional, Lavery, Anita, additional, McGuigan, Andrew, additional, Douglas, Rosalie, additional, Mcmanus, Damian, additional, Horne, Joanne, additional, Walker, Robert, additional, Mir, Hira, additional, Terlizzo, Monica, additional, Kamarajah, Sivesh K, additional, Santaolalla, Aida, additional, Maisey, Nick, additional, Lumsden, Ailsa, additional, Ngan, Sarah, additional, Kelly, Mark, additional, Baker, Cara R, additional, Kumar, Sacheen, additional, Lagergren, Jesper, additional, Allum, William H, additional, Gossage, James A, additional, Griffiths, Ewan, additional, Grabsch, Heike I, additional, Turkington, Richard C, additional, Underwood, Tim, additional, Smyth, Elizabeth, additional, Fitzgerald, Rebecca, additional, Cunningham, David, additional, and Davies, Andrew R, additional

Published
2022
Full Text
View/download PDF

39. 577. FDG PT-CT METABOLIC TUMOUR AND NODAL RESPONSE AS A PREDICTOR OF PATHOLOGICAL RESPONSE AND SURVIVAL IN PATIENTS WITH OESOPHAGEAL ADENOCARCINOMA

Author

Moore, Jonathan, primary, Subesinghe, Manil, additional, Santaolalla, Aida, additional, Green, Michael, additional, Deere, Harriet, additional, Van Hemelrijck, Mieke, additional, Lagergren, Jesper, additional, Chicklore, Sugama, additional, Maisey, Nick, additional, Kelly, Mark, additional, Gossage, James A, additional, Baker, Cara R, additional, and Davies, Andrew R, additional

Published
2022
Full Text
View/download PDF

43. sj-docx-1-uro-10.1177_20514158211065949 ��� Supplemental material for MRI-based nomogram for the prediction of prostate cancer diagnosis: A multi-centre validated patient���physician decision tool

Author

Chau, Edwin M, Russell, Beth, Santaolalla, Aida, Van Hemelrijck, Mieke, McCracken, Stuart, Page, Toby, Liyanage, Sidath H, Aning, Jonathan, Gnanapragasam, Vincent J, and Acher, Peter

Subjects
111708 Health and Community Services, FOS: Clinical medicine, 111799 Public Health and Health Services not elsewhere classified, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified
Abstract

Supplemental material, sj-docx-1-uro-10.1177_20514158211065949 for MRI-based nomogram for the prediction of prostate cancer diagnosis: A multi-centre validated patient���physician decision tool by Edwin M Chau, Beth Russell, Aida Santaolalla, Mieke Van Hemelrijck, Stuart McCracken, Toby Page, Sidath H Liyanage, Jonathan Aning, Vincent J Gnanapragasam and Peter Acher in Journal of Clinical Urology

Published
2022
Full Text
View/download PDF

44. Effect of peri-operative chemotherapy regimen on survival in the treatment of locally advanced oesophago-gastric adenocarcinoma – A comparison of the FLOT and ‘MAGIC’ regimens

Author

Moore, Jonathan L., primary, Kumar, Sacheen, additional, Santaolalla, Aida, additional, Patel, Pranav H., additional, Kapiris, Matthaios, additional, Van Hemelrijck, Mieke, additional, Maisey, Nick, additional, Hill, Mark, additional, Lagergren, Jesper, additional, Gossage, James A., additional, Kelly, Mark, additional, Chaudry, Asif, additional, Allum, William H., additional, Baker, Cara R., additional, Cunningham, David, additional, Davies, Andrew R., additional, Jacques, A., additional, Griffin, N., additional, Goh, V., additional, Ngan, S., additional, Owczarczyk, K., additional, Lumsden, A., additional, Qureshi, A., additional, Deere, H., additional, Green, M., additional, Chang, F., additional, Mahadeva, U., additional, Gill-Barman, B., additional, George, S., additional, Ong, M., additional, Waters, J., additional, Cominos, M., additional, Sevitt, T., additional, Hynes, O., additional, Tham, G., additional, Bott, R.K., additional, Dunn, J.M., additional, and Zeki, S.S., additional

Published
2022
Full Text
View/download PDF

45. Exercise prehabilitation during neoadjuvant chemotherapy may enhance tumour regression in oesophageal cancer: results from a prospective non-randomised trial

Author

Zylstra, Janine, primary, Whyte, Greg P, additional, Beckmann, Kerri, additional, Pate, James, additional, Santaolalla, Aida, additional, Gervais-Andre, Louise, additional, Russell, Beth, additional, Maisey, Nick, additional, Waters, Justin, additional, Tham, Gemma, additional, Lagergren, Jesper, additional, Green, Michael, additional, Kelly, Mark, additional, Baker, Cara, additional, Van Hemelrijck, Mieke, additional, Goh, Vicky, additional, Gossage, James, additional, Browning, Mike, additional, and Davies, Andrew, additional

Published
2022
Full Text
View/download PDF

47. Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium

Author

Olivier, Jonathan, primary, Li, Weiyu, additional, Nieboer, Daan, additional, Helleman, Jozien, additional, Roobol, Monique, additional, Gnanapragasam, Vincent, additional, Frydenberg, Mark, additional, Sugimoto, Mikio, additional, Carroll, Peter, additional, Morgan, Todd M., additional, Valdagni, Riccardo, additional, Rubio-Briones, Jose, additional, Robert, Grégoire, additional, Stricker, Phillip, additional, Hayen, Andrew, additional, Schoots, Ivo, additional, Haider, Masoom, additional, Moore, Caroline M., additional, Denton, Brian, additional, Villers, Arnauld, additional, Trock, Bruce, additional, Ehdaie, Behfar, additional, Filson, Christopher, additional, Logothetis, Christopher, additional, Morgan, Todd, additional, Klotz, Laurence, additional, Pickles, Tom, additional, Hyndman, Eric, additional, Moore, Caroline M, additional, Van Hemelrijck, Mieke, additional, Dasgupta, Prokar, additional, Bangma, Chris, additional, Semjonow, Axel, additional, Rannikko, Antti, additional, Perry, Antoinette, additional, Hugosson, Jonas, additional, Bjartell, Anders, additional, Hefermehl, Lukas, additional, Lui Shiong, Lee, additional, Ha Chung, Byung, additional, van der Kwast, Theo, additional, Hulsen, Tim, additional, van der Linden, Wim, additional, Ruwe, Boris, additional, van Hooft, Peter, additional, Steyerberg, Ewout, additional, Boutros, Paul, additional, Guo, Wei, additional, Benfante, Nicole, additional, Cowan, Janet, additional, Patil, Dattatraya, additional, Park, Lauren, additional, Ferrante, Stephanie, additional, Mamedov, Alexandre, additional, LaPointe, Vincent, additional, Crump, Trafford, additional, Stavrinides, Vasilis, additional, Kimberly-Duffell, Jenna, additional, Santaolalla, Aida, additional, Olivier, Jonathan, additional, Rancati, Tiziana, additional, Ahlgren, Helén, additional, Mascarós, Juanma, additional, Löfgren, Annica, additional, Lehmann, Kurt, additional, Han Lin, Catherine, additional, Cusick, Thomas, additional, Hirama, Hiromi, additional, Suk Lee, Kwang, additional, Jenster, Guido, additional, Auvinen, Anssi, additional, van Bochove, Kees, additional, Kouspou, Michelle, additional, and Paich, Kellie, additional

Published
2022
Full Text
View/download PDF

48. Comparison of Characteristics, Follow-up and Outcomes of Active Surveillance for Prostate Cancer According to Ethnicity in the GAP3 Global Consortium Database

Author

Beckmann, Kerri, primary, Santaolalla, Aida, additional, Helleman, Jozien, additional, Carroll, Peter, additional, Ha Chung, Byung, additional, Shiong Lee, Lui, additional, Perry, Antoinette, additional, Rubio-Briones, Jose, additional, Sugimoto, Mikio, additional, Trock, Bruce, additional, Valdagni, Riccardo, additional, Dasgupta, Prokar, additional, Van Hemelrijck, Mieke, additional, Elhage, Oussama, additional, Ehdaie, Behfar, additional, Filson, Christopher, additional, Logothetis, Christopher, additional, Morgan, Todd, additional, Klotz, Laurence, additional, Pickles, Tom, additional, Hyndman, Eric, additional, Moore, Caroline, additional, Gnanapragasam, Vincent, additional, Bangma, Chris, additional, Roobol, Monique, additional, Villers, Arnauld, additional, Robert, Grégoire, additional, Semjonow, Axel, additional, Rannikko, Antti, additional, Hugosson, Jonas, additional, Bjartell, Anders, additional, Hefermehl, Lukas, additional, Lui Shiong, Lee, additional, Frydenberg, Mark, additional, Stricker, Phillip, additional, van der Kwast, Theo, additional, van der Linden, Wim, additional, Hulsen, Tim, additional, Ruwe, Boris, additional, van Hooft, Peter, additional, Steyerberg, Ewout, additional, Nieboer, Daan, additional, Beckmann, Kerri, additional, Denton, Brian, additional, Hayen, Andrew, additional, Boutros, Paul, additional, Guo, Wei, additional, Benfante, Nicole, additional, Cowan, Janet, additional, Patil, Dattatraya, additional, Park, Lauren, additional, Ferrante, Stephanie, additional, Mamedov, Alexandre, additional, LaPointe, Vincent, additional, Crump, Trafford, additional, Stavrinides, Vasilis, additional, Kimberly-Duffell, Jenna, additional, Olivier, Jonathan, additional, Rancati, Tiziana, additional, Ahlgren, Helén, additional, Mascarós, Juanma, additional, Löfgren, Annica, additional, Lehmann, Kurt, additional, Han Lin, Catherine, additional, Cusick, Thomas, additional, Hirama, Hiromi, additional, Suk Lee, Kwang, additional, Jenster, Guido, additional, Auvinen, Anssi, additional, Haider, Masoom, additional, van Bochove, Kees, additional, Kouspou, Michelle, additional, and Paich, Kellie, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results